Fas ligand gene transfer to renal allografts in rats: Effects on allograft survival

Transplantation

Volumn 65, Issue 2, 1998, Pages 155-160

  Swenson, Kim M ^a,b   Bibo, K E ^a   Wang, Tao ^a   Markowitz, Jay S ^a   Maggard, Melinda A ^a   Spear, Gerald S ^c   Imagawa, David K ^a   Goss, John A ^a   Busuttil, Ronald W ^a   Seu, Philip ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FAS LIGAND; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN; RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE; GENE TRANSFER; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0345628010     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801270-00002     Document Type: Article

References (26)

1. Suda T, Okazaki T, Naito Y, et al. Expression of Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806.
2. Esser MT, Krishnamurthy B, Braciale VL. Distinct T cell receptor signaling requirements for perform- or FasL-mediated cytotoxicity. J Exp Med 1996; 183: 1697.
3. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373: 441.
4. van Parijs L, Abbas A. Role of Fas-mediated cell death in the regulation of immune responses. Curr Opin Immunol 1996; 8: 355.
5. Ju S, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373: 444.
6. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373: 438.
7. Rothstein TL, Wang JK, Panka DJ, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163.
8. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995; 16: 39.
9. Renno T, Hahne M, Tschopp J, MacDonald HR. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med 1996; 183: 431.
10. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630.
11. Korbutt GS, Elliott JF, Rajotte RV. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 1997; 46: 317.
12. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273: 109.
13. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
14. Graham FL, Prevec LA, Schneider M. Cloning and expression of glycoprotein genes in human adenovirus vectors: technological advances in vaccine development. New York: Alan R. Liss, 1988: 243.
15. Graham FL, Van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456.
16. Strand S, Hofmann WJ, Hug H, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells: a mechanism of immune evasion? Nat Med 1996; 2: 1361.
17. O'Connell J, O'Sullivan, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075.
18. Hahne M, Rimoldi D, Schroter P, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 264: 1363.
19. Chervonsky AV, Wang Y, Wong FS, et al. The role of Fas in autoimmune diabetes. Cell 1997; 89: 17.
20. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet B cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943.
21. Watanabe FR, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274.
22. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335.
23. Ehl S, Hoffman-Rohrer U, Nagata S, Hengartner H, Zinkenagl R. Different susceptibility of cytotoxic T cells to CD95 (Fas/ Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol 1996; 156: 2357.
24. Pielsticker K, Thoenes G. Vascular transplant rejection of rat renal allografts across strong histocompatability barriers. Virchows Arch B Cell Pathol 1976; 21: 349.
25. Abbas AK, Corson JM, Carpenter CB, Strom TB, Merrill JP, Dammin GJ. Immunologic enhancement of rat renal allografts. III. Immunopathologic lesions and rejection in long-surviving passively enhance grafts. Am J Pathol 1975; 79: 255.
26. Bradley JA, Mason DW, Morris PJ. Evidence that rat renal allografts are rejected by cytotoxic T cells and not by nonspecific effectors. Transplantation 1985; 39: 169.